ReviewClinical and experimental medicine2025
Liquid biopsy in lung cancer screening: rationale, progress, opportunities and challenges.
Review in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical research advances in thoracic surgery and thoracic oncology in 2025: a panoramic narrative review.Journal of thoracic disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer (LC) remains the leading cause of cancer-related deaths globally. Liquid biopsy offers an accurate and non-invasive screening approach for early detection of LC overcoming the limitations of the current recommended low-dose computed tomography (LDCT). In the current review, we summarized the latest advancements in liquid biopsy for LC screening, evaluating the biological relevance, predictive accuracy, and detection techniques associated with various biomarkers including circulating tumor DNA, proteins, and metabolites. We also addressed the unresolved questions of how to integrate liquid biopsy into routine clinical practice to improve LC outcomes by cost-effective analysis. It is hoped that this study can shed light upon the future development of LC screening methods and provide insights for the potential integration of liquid biopsy into the current clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.